Related Experiment Video

Updated: Jun 2, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease

J Li1, Y J Wang, M Zhang

  • 1Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, No. 10 Changjiang Branch Road, Daping, Chongqing, China.

Neurology
|April 15, 2011
PubMed
Abstract

Insights

Vascular risk factors (VRF) accelerate cognitive decline and increase Alzheimer's disease (AD) risk in mild cognitive impairment (MCI). Treating these factors, including hypertension and diabetes, may reduce the progression from MCI to AD dementia.

Area of Science:

  • Neuroscience
  • Gerontology
  • Public Health

Background:

  • Vascular risk factors (VRF) are increasingly linked to cognitive decline.
  • Understanding the impact of VRF on the progression of mild cognitive impairment (MCI) to Alzheimer disease (AD) dementia is crucial for developing effective interventions.

Purpose of the Study:

  • To investigate the association between vascular risk factors (VRF) and the conversion rate from mild cognitive impairment (MCI) to Alzheimer disease (AD) dementia.
  • To examine the effect of treating VRF on the progression from MCI to AD dementia.

Main Methods:

  • A cohort of 837 subjects with MCI was followed annually for 5 years.
  • Mixed random effects regression and Cox proportional hazard models were used to analyze the association between VRF and cognitive/functional progression and dementia conversion.
  • The study examined the impact of treated versus untreated VRF on MCI to AD dementia progression.

Main Results:

  • Subjects with VRF showed faster cognitive and functional decline compared to those without.
  • Hypertension, diabetes, cerebrovascular diseases, and hypercholesterolemia were identified as VRF that increased dementia conversion risk.
  • Complete treatment of all VRF was associated with a lower risk of dementia conversion, as was the treatment of individual VRF like hypertension, diabetes, and hypercholesterolemia.

Conclusions:

  • Vascular risk factors significantly increase the risk of developing Alzheimer disease dementia in individuals with MCI.
  • Active intervention and treatment of VRF are associated with a reduced risk of progression from MCI to AD dementia.
  • These observational findings suggest that managing vascular risk factors may be a viable strategy to slow or prevent the transition to AD dementia.

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...